DelveInsight’s Factor D Complement Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging factor D complement inhibitors, market share of ...
Factor D complement inhibitors companies working in the market are AstraZeneca, Alexion (a subsidiary of AstraZeneca), BioCryst, and others. ALBANY, NY, UNITED STATES, December 4, 2024 /EINPresswire / ...
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in a proof-of-concept clinical trial ...
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and ...
Achillion Pharmaceuticals, Inc.ACHN announced positive interim data from clinical studies evaluating its factor D inhibitors - ACH-4471, ACH-5228 and ACH-5548. Two phase II studies are evaluating the ...
(MENAFN- GlobeNewsWire - Nasdaq) The factor D complement inhibitor market is projected to experience rapid growth due to the expansion of indications for already approved therapies, such as danicopan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback